# Kai-Christian Sonntag

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 35 papers | 2,586 citations | 22 h-index | 38 g-index |
| 38 ext. papers | 2,844 ext. citations | 5.5 avg, IF | 4.9 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 35 | Brain cells derived from Alzheimer's disease patients have multiple specific innate abnormalities in energy metabolism. *Molecular Psychiatry*, **2021**, | 15.1 | 16 |
| 34 | Hypothesis and Theory: Characterizing Abnormalities of Energy Metabolism Using a Cellular Platform as a Personalized Medicine Approach for Alzheimer's Disease. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 697578 | 5.7 | 1 |
| 33 | Reactive oxygen species-sensitive nanophotosensitizers of aminophenyl boronic acid pinacol ester conjugated chitosan-g-methoxy poly(ethylene glycol) copolymer for photodynamic treatment of cancer. *Biomedical Materials (Bristol)*, **2020**, 15, 055034 | 3.5 | 4 |
| 32 | The use of laser capture microdissection to identify specific pathways and mechanisms involved in impulsive choice in rats. *Heliyon*, **2019**, 5, e02254 | 3.6 | 0 |
| 31 | Gene expression profile associated with postnatal development of pyramidal neurons in the human prefrontal cortex implicates ubiquitin ligase E3 in the pathophysiology of schizophrenia onset. *Journal of Psychiatric Research*, **2018**, 102, 110-117 | 5.2 | 6 |
| 30 | Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. *Progress in Neurobiology*, **2018**, 168, 1-20 | 10.9 | 47 |
| 29 | Cell Type-Specific Laser Capture Microdissection for Gene Expression Profiling in the Human Brain. *Methods in Molecular Biology*, **2018**, 1723, 203-221 | 1.4 | 3 |
| 28 | Laser microdissection and gene expression profiling in the human postmortem brain. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2018**, 150, 263-272 | 3 | 2 |
| 27 | Late-onset Alzheimer's disease is associated with inherent changes in bioenergetics profiles. *Scientific Reports*, **2017**, 7, 14038 | 4.9 | 63 |
| 26 | MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons. *Molecular Neurobiology*, **2016**, 53, 95-108 | 6.2 | 36 |
| 25 | Limited predictability of postmortem human brain tissue quality by RNA integrity numbers. *Journal of Neurochemistry*, **2016**, 138, 53-9 | 6 | 25 |
| 24 | Differentiation of oligodendrocyte precursors is impaired in the prefrontal cortex in schizophrenia. *Schizophrenia Research*, **2015**, 169, 374-380 | 3.6 | 56 |
| 23 | Midbrain dopamine neurons in Parkinson's disease exhibit a dysregulated miRNA and target-gene network. *Brain Research*, **2015**, 1618, 111-21 | 3.7 | 59 |
| 22 | Molecular profiles of pyramidal neurons in the superior temporal cortex in schizophrenia. *Journal of Neurogenetics*, **2014**, 28, 53-69 | 1.6 | 56 |
| 21 | miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. *Neurobiology of Aging*, **2014**, 35, 1712-21 | 5.6 | 94 |
| 20 | Selection Based on FOXA2 Expression Is Not Sufficient to Enrich for Dopamine Neurons From Human Pluripotent Stem Cells. *Stem Cells Translational Medicine*, **2014**, 3, 1032-42 | 6.9 | 11 |
| 19 | Molecular profiles of parvalbumin-immunoreactive neurons in the superior temporal cortex in schizophrenia. *Journal of Neurogenetics*, **2014**, 28, 70-85 | 1.6 | 50 |

| | | | |
|---|---|---|---|
| 18 | Fast and efficient neural conversion of human hematopoietic cells. *Stem Cell Reports*, **2014**, 3, 1118-31 | 8 | 31 |
| 17 | Converging miRNA functions in diverse brain disorders: a case for miR-124 and miR-126. *Experimental Neurology*, **2012**, 235, 427-35 | 5.7 | 75 |
| 16 | Detection of intranasally delivered bone marrow-derived mesenchymal stromal cells in the lesioned mouse brain: a cautionary report. *Stem Cells International*, **2011**, 2011, 586586 | 5 | 14 |
| 15 | Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. *PLoS ONE*, **2010**, 5, e8856 | 3.7 | 95 |
| 14 | MicroRNAs and deregulated gene expression networks in neurodegeneration. *Brain Research*, **2010** , 1338, 48-57 | 3.7 | 104 |
| 13 | Proteasome activator enhances survival of Huntington's disease neuronal model cells. *PLoS ONE*, **2007**, 2, e238 | 3.7 | 94 |
| 12 | Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. *Stem Cells*, **2007**, 25, 411-8 | 5.8 | 214 |
| 11 | Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. *Stem Cells*, **2007**, 25, 2257-68 | 5.8 | 263 |
| 10 | Immature and neurally differentiated mouse embryonic stem cells do not express a functional Fas/Fas ligand system. *Stem Cells*, **2007**, 25, 2551-8 | 5.8 | 23 |
| 9 | Immunological Considerations in CNS Transplants **2007**, 305-326 | | |
| 8 | Specific microRNAs modulate embryonic stem cell-derived neurogenesis. *Stem Cells*, **2006**, 24, 857-64 | 5.8 | 552 |
| 7 | Tailoring human embryonic stem cells for neurodegenerative disease therapy. *Current Opinion in Investigational Drugs*, **2006**, 7, 614-8 | | 9 |
| 6 | Stem cells may reshape the prospect of Parkinson's disease therapy. *Molecular Brain Research*, **2005** , 134, 34-51 | | 45 |
| 5 | Implementations of translational medicine. *Journal of Translational Medicine*, **2005**, 3, 33 | 8.5 | 18 |
| 4 | Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. *Human Molecular Genetics*, **2005**, 14, 1709-25 | 5.6 | 295 |
| 3 | Human Fas-ligand expression on porcine endothelial cells does not protect against xenogeneic natural killer cytotoxicity. *Xenotransplantation*, **2004**, 11, 43-52 | 2.8 | 10 |
| 2 | Generalized brain and skin proteasome inhibition in Huntington's disease. *Annals of Neurology*, **2004**, 56, 319-28 | 9.4 | 151 |
| 1 | Tolerance to solid organ transplants through transfer of MHC class II genes. *Journal of Clinical Investigation*, **2001**, 107, 65-71 | 15.9 | 59 |